Skip to main content
SpringerLink
Log in
Book cover

HRT and Osteoporosis pp 177–195Cite as

Oestrogens and Cancer

  • Conference paper

  • 91 Accesses

Abstract

The fear that hormone replacement therapy (HRT) may provoke cancer currently prevents many women from seeking such treatment and many physicians from prescribing it. Although the evidence linking oestrogens and cancer is reassuring for most tumours, there are still uncertainties. This chapter discusses the current evidence for an association of HRT with genital cancers, cancers of the large bowel and melanomas.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith DC, Prentice R, Thompson DJ et al. Association of exogenous estrogens and endometrial cancer. N Engl J Med 1975; 293:1164–7.

    Article  PubMed  CAS  Google Scholar 

  2. Ziel H, Finkle W. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293:1167–70.

    Article  PubMed  CAS  Google Scholar 

  3. Mack TM, Pike MC, Henderson BE et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294:1262–7.

    Article  PubMed  CAS  Google Scholar 

  4. Chu J, Schweid AI, Weiss NS. Survival among women with endometrial cancer: a comparison of estrogen users and non-users. Am J Obstet Gynecol 1982; 143:569–75.

    PubMed  CAS  Google Scholar 

  5. Elwood JM, Boyes DA. Clinical and pathological features and survival of cancer patients in relation to prior use of estrogens. Gynecol Oncol 1980; 10:173–80.

    Article  PubMed  CAS  Google Scholar 

  6. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term unopposed estrogen replacement therapy. Maturitas 1988; 10:271–82.

    Article  PubMed  CAS  Google Scholar 

  7. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989; 59:445–7.

    Article  PubMed  CAS  Google Scholar 

  8. Whithead MI, King RJB, McQueen J, Campbell S. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestin therapy. J R Soc Med 1979; 72:322–7.

    Google Scholar 

  9. Studd JWW, Thorn MH, Paterson MEL, Wade-Evans T. The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous oestrogens. In: Pasetto N, Paoletti R, Ambrus JL, eds. The menopause and postmenopause. Lancaster: MTP, 1980; 127–39.

    Google Scholar 

  10. Whitehead MI, Townsend PT, Pryse-Davies J et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982; 27:539–48.

    PubMed  CAS  Google Scholar 

  11. Gambrell RD. Prevention of endometrial cancer with progestogens. Maturitas 1986; 8:159–68.

    Article  PubMed  Google Scholar 

  12. Persson I, Adami H-O, Bergkvist L et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989;298:147–51.

    Article  CAS  Google Scholar 

  13. Franks AL, Kendrick JS, Tyler CW, Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. Am J Obstet Gynecol 1987; 156:20–3.

    PubMed  CAS  Google Scholar 

  14. Crook D, Godsland IF, Wynn V. Ovarian hormones and plasma lipoproteins. In: Studd JWW, Whitehead MI, eds. The menopause. Oxford: Blackwell Scientific Publications, 1988; 168–80.

    Google Scholar 

  15. Silverstolpe G, Gustafson A, Samsioe G, Svanborg A. Lipid metabolic studies in oophorectomised women: effects of three different progestogens. Acta Obstet Gynecol Scand 1979; 88:89–95.

    Article  Google Scholar 

  16. Ottoson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy. A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151:746–50.

    Google Scholar 

  17. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981; 305:1599–604.

    Article  PubMed  CAS  Google Scholar 

  18. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Effect of dydrogesterone on the oestrogenised postmenopausal endometrium. Br J Obstet Gynaecol 1986; 93:55–62.

    Article  PubMed  CAS  Google Scholar 

  19. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertil Steril 1986; 45:345–52.

    PubMed  CAS  Google Scholar 

  20. Fraser DI, Parsons A, Whitehead MI, Wordsworth J, Stuart G, Pryse-Davis J. The optimal dose of oral norethindrone for addition to transdermal estradiol; a multicenter study. Fertil Steril 1990 (in press).

    Google Scholar 

  21. Padwick ML, Pryse-Davies J, Whitehead MI. A simple method for determining the optimal dose of progestin in postmenopausal women receiving estrogens. N Engl J Med 1986; 315:19.

    Article  Google Scholar 

  22. Staland B. Continuous treatment with natural oestrogens and progestogens: a method to avoid endometrial hyperstimulation. Maturitas 1981; 3:145–56.

    Article  PubMed  CAS  Google Scholar 

  23. Magos AL, Brincat M, Studd JWW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhoea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985; 65:496–9.

    PubMed  CAS  Google Scholar 

  24. Whitehead MI. Prevention of endometrial abnormalities. In: Greenblatt RB, ed. A modern approach to the perimenopausal years. Berlin: de Gruyter, 1986; 189–206.

    Google Scholar 

  25. Cramer DW, Devasa SS, Welch WR. Trends in the incidence in endometrioid and clear-cell cancers of the ovary in the United States. Am J Epidemiol 1981; 114:201–8.

    PubMed  CAS  Google Scholar 

  26. Weiss NS, Lyon JL, Krishnamurthy S, Ditert SE, Liff JM, Daling JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982; 68:95–8.

    PubMed  CAS  Google Scholar 

  27. La Vecchia C, Liberati A, Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982; 69:1207.

    PubMed  Google Scholar 

  28. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. Reproductive experiences and family history. J Natl Cancer Inst 1983; 71:711–16.

    PubMed  CAS  Google Scholar 

  29. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94:620–35.

    Article  PubMed  CAS  Google Scholar 

  30. Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981; 43:72–8.

    Article  PubMed  CAS  Google Scholar 

  31. Trichopolous D, Macmahon B, Cole P. The menopause and breast cancer risk. J Natl Cancer Inst 1972; 48:605–13.

    Google Scholar 

  32. Ross RK, Paganini-Hill A, Gerkins VR. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243:1635–40.

    Article  PubMed  CAS  Google Scholar 

  33. Brinton LA, Hoover RN, Szklo M, Fraumeni JF. Menopausal estrogen use and risk of breast cancer. Cancer 1981; 47:2517–22.

    Article  PubMed  CAS  Google Scholar 

  34. Hoover R, Glass A, Finkle WD et al. Conjugated estrogens and breast cancer risk. J Natl Cancer Inst 1981; 67:815–20.

    PubMed  CAS  Google Scholar 

  35. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 1984; 54:139–44.

    Article  PubMed  CAS  Google Scholar 

  36. Kelsey JL, Fischer DB, Holford JR et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67:327–33.

    PubMed  CAS  Google Scholar 

  37. Kaufman DW, Miller DR, Rosenberg L, Helmrich SP. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984; 252:63–7.

    Article  PubMed  CAS  Google Scholar 

  38. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257:209–15.

    Article  PubMed  CAS  Google Scholar 

  39. Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54:825–32.

    Article  PubMed  CAS  Google Scholar 

  40. Thomas DB, Persin JP, Hutchinson WB. Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases. J Natl Cancer Inst 1982; 69:1017–25.

    PubMed  CAS  Google Scholar 

  41. Dupont WD, Page DL, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989; 63:948–57.

    Article  PubMed  CAS  Google Scholar 

  42. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen-progestin replacement. N Engl J Med 1989; 321:293–7.

    Article  PubMed  CAS  Google Scholar 

  43. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42:832–8.

    Article  PubMed  CAS  Google Scholar 

  44. Gambrell RD. Role of progestogens in the prevention of breast cancer. Maturitas 1986; 8:169–75.

    Article  PubMed  Google Scholar 

  45. Anderson TJ, Fergusson DJP, Raab GM. Cell turnover in the resting human breast; influences of parity, contraceptive pill, age, and laterality. Br J Cancer 1982; 46:376–82.

    Article  PubMed  CAS  Google Scholar 

  46. Whitehead MI, Lobo RA. Progestogen use in postmenopausal women. Consensus Conference. Lancet 1988; ii:1243–4.

    Article  Google Scholar 

  47. Abdalla HI, Hart DM, Lindsay R et al. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66:789–92.

    PubMed  CAS  Google Scholar 

  48. Stoll BA. Effect of Lyndiol, an oral contraceptive, on breast cancer. Br Med J 1967; 1:150–3.

    Article  PubMed  CAS  Google Scholar 

  49. Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet 1988; i:1278–9.

    Article  Google Scholar 

  50. Schottenfield D, Berg JW, Vitsky B. Incidence of multiple primary cancers. II. Index cancers arising in the stomach and digestive system. J Natl Cancer Inst 1969; 43: 77–86.

    Google Scholar 

  51. Weiss S, Darling JR, Chow WH. Incidence of cancer of the large bowel in relation to reproductive and hormonal factors. J Natl Cancer. Inst 1981; 67:57–60.

    PubMed  CAS  Google Scholar 

  52. Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983; 71:703–9.

    PubMed  CAS  Google Scholar 

  53. Davis FG, Furner SE, Persky V, Koch M. The influence of parity and exogenous female hormones on the risk of colorectal cancer. Int J Cancer 1989; 43:587–90.

    Article  PubMed  CAS  Google Scholar 

  54. Markland FS, Horn D. Steroid hormone receptor studies in a melanoma model system. J Supramol Struct 1980; 13: 35–46.

    Article  PubMed  CAS  Google Scholar 

  55. Walker MJ, Beattie CW, Briele HA, Patel MK, Das Gupta TK. Estrogen receptor in malignant melanoma. J Clin Oncol 1987; 5:1254–61.

    Google Scholar 

  56. Proctor JW, Auclair BG, Stockowski L. Brief communications; endocrine factors and the growth and spread of B16 melanoma. J Natl Cancer Inst 1976; 57:1197–8.

    PubMed  CAS  Google Scholar 

  57. Lopez RE, Bhakoo H, Paolini NS, Rosen F, Holyoke ED, Goldrosen MH. Effect on estrogen on the growth of B16 melanoma. Surg Forum 1978; 29:153–4.

    PubMed  CAS  Google Scholar 

  58. Shaw HM, Milton GW, Farago G, McCarthy WH. Endocrine influences on survival from malignant melanoma. Cancer 1978; 42:669–77.

    Article  PubMed  CAS  Google Scholar 

  59. Pack GT, Scharnagel IM. The prognosis for malignant melanoma in pregnant women. Cancer 1951;4:324–34.

    Article  PubMed  CAS  Google Scholar 

  60. Shiu MH, Schottenfield D, Maclean B, Fortner JG. Adverse effects of pregnancy on melanoma. A reappraisal. Cancer 1976; 37:181–7.

    Article  PubMed  CAS  Google Scholar 

  61. Sadoff L, Winkeley J, Tyson S. Is malignant melanoma an estrogen dependent tumour? Oncology 1973; 27:244–57.

    Article  PubMed  CAS  Google Scholar 

  62. Adler S, Gaeta J. Malignant melanoma. In: Helm F, ed. Cancer dermatology. Philadelphia, Lea and Febiger, 1979, 141–57.

    Google Scholar 

  63. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94:620–35.

    Article  PubMed  CAS  Google Scholar 

  64. Bergkvist L, Persson, I, Adami HO, Schairer C. Risk factors for breast and endometrial cancer in a cohort of women treated with menopausal oestrogens. Int J Epidemiol 1988; 17:732–7.

    Article  PubMed  CAS  Google Scholar 

  65. Padwick ML, Pryse-Davies J, Whitehead ML A simple method for determining the optimal dose of progestin in postmenopausal women receiving estrogens. N Engl J Med 1986; 315:19.

    Article  Google Scholar 

Download references

Authors
  1. M. P. Cust
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. F. Gangar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. I. Whitehead
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clarendon Wing, Leeds General Infirmary, Leeds, LS1 3EX, UK

    James O. Drife MD, FRCS Ed, FRCOG (Professor of Obstetrics and Gynaecology) (Professor of Obstetrics and Gynaecology)

  2. King’s College Hospital, London, SE5 9RS, UK

    John W. W. Studd MD, BS, FRCOG (Consultant Obstetrician and Gynaecologist, Director) (Consultant Obstetrician and Gynaecologist, Director)

  3. The Menopause Clinic, Dulwich Hospital, East Dulwich Grove, London, SE22 8PT, UK

    John W. W. Studd MD, BS, FRCOG (Consultant Obstetrician and Gynaecologist, Director) (Consultant Obstetrician and Gynaecologist, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag London Limited

About this paper

Cite this paper

Cust, M.P., Gangar, K.F., Whitehead, M.I. (1990). Oestrogens and Cancer. In: Drife, J.O., Studd, J.W.W. (eds) HRT and Osteoporosis. Springer, London. https://doi.org/10.1007/978-1-4471-1799-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1799-5_15

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1801-5

  • Online ISBN: 978-1-4471-1799-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation